The Phase II trials will evaluate the drug candidate in patients with post herpetic neuralgia (PHN) and overactive bladder.
AGN-214868 was discovered under the partnership using Syntaxin’s proprietary discovery platform.
Under the agreement, Allergan will be responsible for clinical development, marketing and sales of identified drug candidates, while Syntaxin will receive milestone payments and royalties on product sales.